New pill shows promise for early Parkinson's motor symptoms

NCT ID NCT06596005

Completed Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 trial tested an experimental capsule called TJ0113 in 149 people with early-stage Parkinson's disease. Participants took either 200 mg, 400 mg, or a placebo daily for 12 weeks. The main goal was to see if the drug improved motor symptoms, measured by a standard rating scale. The study is complete, and results are pending.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TJ0113 capsule
What this could lead to: If successful, this could point toward a new oral treatment option to help control motor symptoms in early Parkinson's disease.
What could go wrong: This is an early Phase 2 trial with only 149 participants, so results may not apply to all patients. The study is completed but not yet published, and the drug may not improve symptoms or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Second Affiliated Hospital, School of Medicine, Zhejiang University, China

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.